NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate securities claims on behalf of shareholders of ESS Tech, Inc. (NYSE: GWH, GWH.WT) resulting from allegations that ESS Tech may have
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) resulting from allegations that Phathom may have
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Provident Bancorp, Inc. (NASDAQ: PVBC) resulting from allegations that Provident may have issued
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Core Scientific, Inc. (NASDAQ: CORZ) between January 3, 2022 and October 26, 2022, both dates inclusive (the “Class
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bird Global, Inc. (NYSE: BRDS) between May 14, 2021 and November 14, 2022, both dates inclusive (the “Class Period”),
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given
TEMECULA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is proud to announce its first on-site FAT testing at their new Marine facility in